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Introduction
Breast cancer is the second leading cause of cancer-related deaths among women, with as many as 40% relapsing with metastatic disease after therapy, and conventional therapies have been able to effectively shrink solid tumors, but have failed to produce long-term clinical remissions without recurrence and metastasis (Morrison et al., 2008) . Recently, it has been suggested that cancer stem cells, which represent a subset of tumor cells, are responsible for the origin and maintenance of tumors. Moreover, cancer stem cells are believed to be the main cause of metastasis and recurrences of cancer because of their strong tumor initiating abilities and resistance to conventional therapies (Al-Hajj et al., 2004; Morrison et al., 2008; Sheridan et al., 2006) .
A transmembrane glycoprotein, CD44, first known to be involved in cell-cell interaction and cell adhesion, has been identified as a key cell-surface marker for cancer stem cells in pancreas cancer, prostate cancer, head and neck squamous cell carcinoma and breast cancer (Al-Hajj et al., 2003; Collins et al., 2005; Li et al., 2007; Prince et al., 2007) . Induction of CD44 expression in human breast cancer cell lines has been shown to enhance self-renewal, mammosphere growth, and drug resistance, demonstrating functional roles of CD44 in breast cancer stem cells (To et al., 2010) . CD44 is also known as an important mediator for the response of cells to their cellular microenvironment (Ponta et al., 2003) . Al-Hajj et al first identified breast cancer stem cells from human breast cancer specimens, which are rich in CD44 + /CD24 -/low cells, and showed that this distinct population of cells had exclusive ability to form tumors in mice (Al-Hajj et al., 2003) . Later, Fillmore et al demonstrated that human breast cancer cells contain a defined subpopulation of CD44 + /CD24 -/low cells which can drive tumorigenesis and re-generate tumor cell heterogeneity (Fillmore and Kuperwasser, 2008) . A clinical study also indicated that CD44 + /CD24 -/low cells were enriched in residual breast cancers after conventional therapies (Creighton et al., 2009 ).
This article has not been copyedited and formatted. The final version may differ from this version. (Behbod et al., 2009) . Moreover, the bipotential progenitor properties of MCF10DCIS.com cells, which give rise to not only epithelial cells but also myoepithelial cells
in mouse xenografts, demonstrate the ability of generating heterogeneous cell populations (Hu et al., 2008) , suggesting that the MCF10DCIS.com cell line might be a useful model for studying the efficacy of preventive and therapeutic agents for inhibiting breast cancer stem cells.
Our recent report of in vivo and in vitro inhibitory activities of novel Gemini vitamin D analogs on MCF10DCIS.com cells (Lee et al., 2008) led us to study whether 1α,25(OH) 2 D 3 or Gemini vitamin D analogs regulate cancer stem cell markers such as CD44, which eventually results in inhibition of breast tumorigenesis. 1α,25(OH) 2 D 3 is the key hormone in calcium/phosphate homeostasis and bone mineralization, and an epidemiological study indicates an association between low serum vitamin D levels and increased risk for breast cancer (Deeb et al., 2007) .
However, the clinical application of 1α,25(OH) 2 D 3 for inhibition of breast cancer was limited by hypercalcemic toxicity which was detected in 20 ~ 30% of patients in clinical trials (Deeb et al., 2007; Hellstrom et al., 1990) . Therefore, numerous synthetic vitamin D 3 analogs have been developed for better anti-cancer efficacy with lower toxicity (Hines et al., 2010) . Our studies demonstrated that Gemini vitamin D analogs inhibited the formation and growth of estrogen receptor-positive mammary tumors in vivo without hypercalcemic toxicity (Lee et al., 2008) , and suppressed mammary tumor growth in the ErbB2-overexpressing transgenic mice (Lee et al.,
This article has not been copyedited and formatted. The final version may differ from this version. was administered orally at the dose of 0.03 and 0.1 μg/kg bodyweight, tumor volume and weight were significantly reduced in MCF10DCIS.com xenografted SCID mice (Fig. 1D ). Tumor volume was reduced by BXL0124 treatment at the dose of 0.03 and 0.1 μg/kg body weight by 36% (p<0.05) and 49% (p<0.05), respectively. Tumor weight was decreased by 37% (p<0.05) and 52% (p<0.05) with 0.03 and 0.1 μg/kg body weight of BXL0124 treatment, respectively (Fig. 1D) .
In all animal studies, both intraperitoneal injection and oral administration of BXL0124 at the doses tested did not cause any significant changes in body weights and serum calcium levels, indicating no hypercalcemic toxicity at the given doses ( and variant forms of CD44 (CD44v, 100 ~ 250 kDa) were markedly down-regulated by BXL0124.
The repression of CD44v3 and CD44v6 variants expression by BXL0124 treatment was also shown by using antibodies that specifically recognized individual variant forms (Fig. 3A) . The expression of proliferating cell nuclear antigen (PCNA), a marker for cell proliferation, was also significantly repressed by BXL0124 treatment (Fig. 3A) . In the histological evaluation using H & E staining of mammary tumors, we confirmed that all mammary tumors from the control and BXL0124 treatment groups were determined to be adenocarcinomas (Fig. 3B ). However, both CD44 and PCNA expression levels of MCF10DCIS.com xenograft tumors in nu/nu mice were significantly decreased in BXL0124-treated group when compared to the control (Fig. 3C ).
Three mammary tumors from each group were selected and three representative areas from each tumor were analyzed to quantify the staining intensity by using Scan Scope. The staining intensities of CD44 and PCNA were scored from 3+ (the strongest staining) to 0+ (negative staining) in each individual epithelial cell automatically. In both the control and BXL0124-treated groups, CD44 protein was localized exclusively on the plasma membrane of epithelial cells in mammary tumors. The distribution of cell fraction by CD44 staining intensity in the control group was 48% (3+), 32% (2+) and 20% (1+), whereas BXL0124-treated group showed 15% (3+), 62% (2+) and 23% (1+) of CD44 staining intensity (Fig. 3C) . For PCNA staining, 82% of cells were PCNA-positive in control group whereas 62% of cells were PCNA-positive in BXL0124-treated group (Fig. 3C) . 18% of cells were PCNA-negative in the control group, while 38% of cells were PCNA-negative in the BXL0124-treated group (p<0.01) (Fig. 3C ). (Fig. 4A ). We have also tested the effect of BXL0124 on the CD44 marker in a different cell line, MCF10CA1a, which is known to be a highly aggressive cell line with metastatic capability among the MCF10 cell line series.
BXL0124 also down-regulated the protein expression level of both CD44s and CD44v in MCF10CA1a cells (Fig. 4A) . DAPI staining was used to recognize the nuclear morphology of cells. We found that the CD44 protein was localized specifically in the plasma membrane and the expression level was reduced by BXL0124 treatment without changes of any sub-cellular localization (Fig. 4B) or BXL0124 for 4 h, osteopontin mRNA expression was induced in a dose-dependent manner (Fig. 5D ).
This article has not been copyedited and formatted. The final version may differ from this version. repressed transactivation of the CD44 promoter in a dose-dependent manner, BXL0124 showed a more potent inhibitory effect than 1α,25(OH) 2 D 3 (Fig. 6A) . Recently, p53 was reported to inhibit CD44 expression via binding to a p53-binding sequence on the CD44 promoter (Godar et al., 2008) . Therefore, we determined the involvement of p53 for the repression of CD44 by BXL0124. The repression of CD44 promoter transactivation by BXL0124 was abolished when the p53-binding site of the CD44 promoter was mutated, indicating p53 is necessary for the CD44 repression by BXL0124 (Fig. 6B ).
This article has not been copyedited and formatted. The final version may differ from this version. 
Discussion
Accumulating evidence indicates that cancer stem cells are responsible for tumorinitiation, recurrence, metastasis, and the resistance to conventional chemotherapies (Dick, 2008; Visvader and Lindeman, 2008) . Therefore, these cancer stem cells are becoming a critical target for cancer therapeutics. CD44 is a key cell-surface marker for cancer stem cells in , 2010) . In the present study, BXL0124 decreased the expression of CD44 mRNA and protein (Fig. 4A, 5A and 5B) while inducing the expression of osteopontin mRNA ( Fig. 5C and 5D ) in cultured MCF10DCIS.com cells. Although BXL0124 induced the expression of osteopontin mRNA, the repression of its receptor, CD44, may be the primary contributor to the growth inhibitory effect of BXL0124 on MCF10DCIS.com cells.
Godar et al found that the p53 tumor suppressor inhibits expression of CD44 via binding to a p53-binding sequence in the CD44 promoter in transformed human mammary epithelial cells, suggesting that CD44 repression by p53 is critical for the tumor suppressive action of p53 (Godar et al., 2008) . In the present study, repression of CD44 promoter transactivation by BXL0124 treatment was abolished when the p53-binding site in CD44 promoter was mutated.
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To determine how vitamin D and a Gemini vitamin D analog regulate the expression of CD44,
we also investigated the involvement of the VDR. It is well known that the majority of the biological functions of vitamin D is exerted through binding to VDR (Deeb et al., 2007) . We demonstrated that knock-down of VDR using siRNA resulted in reversing the inhibitory effect of BXL0124 on CD44 repression (Fig. 4D) . Furthermore, we found that putative VDRE sequences are present in the CD44 promoter region (data not shown), suggesting that the VDR liganded by vitamin D or its analog may directly bind to CD44 promoter region to repress its expression.
In conclusion, we demonstrated the repression of CD44 expression by the Gemini vitamin D analog BXL0124 in vivo and in vitro, which is likely via VDR-and p53-dependent mechanisms. Our study suggests novel Gemini vitamin D analogs as potentially useful agents for repressing CD44 expressing cancer stem cells in breast cancer.
